Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali

NCT00889616 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

154

Enrollment

NIH

Sponsor class

Conditions

Malaria

Interventions

DRUG: BSAM2/Alhydrogel + CPG 7909

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)